Publications du service

Principales publications scientifiques du service d'oncologie médicale de l'hôpital Saint Antoine.

2025

  • André T, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.
    Ann Oncol. 2025 Mar;36(3):277-284.    
                                                    
  • André T, et al Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
    Lancet. 2025;405(10476):383-395.

  • Pellat A, et al.  Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024: a retrospective analysis of a monocentric prospective cohort study.
    ESMO Open. 2025 Sep;10(9):105559.

  • Cohen R, et al. Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis.
    ESMO Open. 2025 Mar;10(3):104481. doi: 10.1016/j.esmoop.2025.104481.

  • Vanderbecq Q et al.. Evaluating MRI response criteria in microsatellite instability-high rectal cancer treated with immune checkpoint inhibitors.
    ESMO Open. 2025 Dec 29;11(1):106020.

  • Duval M, et al.  Organ-sparing strategies in patients with MSI/dMMR tumors including Lynch syndro
    me: Current state of the art and future perspectives for clinical decision-making.
    Int J Cancer. 2025

  • André T, et al Microsatellite-Instability-High Metastatic Colorectal Cancer. Reply.
    N Engl J Med. 2025 Feb 13;392(7):726-727.

  • André T,  et al. CheckMate 8HW and the future of dual immunotherapy – Authors' reply. The Lancet, Volume 406, Issue 10516, 2219 - 2220
    Qi C, et al Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.
    Eur J Cancer. 2025 May 2;220:115338.

  • Bachet JB, et al. Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.
    J Clin Oncol. 2025 Jun 20;43(18):2094-2106.

  • Raimondi A, et al.  Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.
    J Clin Oncol. 2025 Nov 10;43(32):3457-3467. doi: 10.1200/JCO-25-00447.

2024

  • Andre T, et al. CheckMate 8HW Investigators.. Nivolumab plus ipilimumab in microsatellite instability-highmetastatic colorectal cancer (mCRC).
    N. Engl. J. Med 2024; 391:2014-2026.

  • Cohen R, et al. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation.
    Eur J Cancer. 2024 Mar;199:113537.

  • Duval M, et al. Performances of preoperative CT scan to predict the pTN stage for MSI/dMMR localized colon cancers.
    ESMO Open. 2024. 2024 Aug;9(8):103678.

  • Chibaudel B, et al. Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.
    J Clin Oncol. 2024

  • André T, Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer.
    Curr Treat Options Oncol. 2024 Oct;25(10):1312-1322.

  • Raghav K, et al Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2024 Sep;25(9):1147-1162.

  • Svrcek M, et al. Improving individualised therapies in localised gastro-oesophageal adenocarcinoma.
    Lancet Oncol. 2024 Sep;25(9):e452-e463.

  • Cervantes B, et al Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions.
    Ther Adv Med Oncol. 2024 Jan 9;16.

  • Logeart J, et al. Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study.
    Clin Colorectal Cancer. 2024 Dec;23(4):346-353.